Olin Corporation OLN

Key data

The business

Olin does three things. Its biggest business, Chlor Alkali Products and Vinyls, splits salt and electricity into chlorine and caustic soda, the starting materials for plastics, water treatment, paper and pharmaceuticals. It runs the largest chlor-alkali system in the world, so its edge is cost: whoever makes a ton of chlorine cheapest wins, and Olin sits low on that curve. The second is Epoxy, resins for coatings, wind blades and electronics. The third is Winchester, which loads ammunition for the U.S. military, police and hunters and operates the government's Lake City plant. The two chemical businesses are deep cyclicals whose prices track global industrial demand and Chinese supply. Winchester is steadier and, right now, the healthiest of the three. In August, Olin agreed to combine with Huntsman into a company called OlinHuntsman, a deal announced but not yet closed.

The numbers

The last five quarters show a business scraping the trough and starting to climb off it.

Q1 2026 was ugly, an $83M loss as a Texas freeze and a planned outage hit. Q2 swung operating income back to positive $46.5M and lifted gross margin to 10% from 8% a year earlier, the cyclical turn showing up in the print.

Revenue fell from $9.4B in 2022 to $6.5B in 2024 and has flatlined near $6.8B since, but earnings collapsed far harder, from $8.94 a share to a full-year loss, because chlorine and epoxy prices dropped faster than costs. That is operating leverage running in reverse. Winchester is what keeps the whole thing afloat at the bottom.

The problem is the balance sheet. Net debt runs about 6.6 times trough cash earnings, interest ate $44.3M last quarter alone, and the company has not covered its interest from operations over the past year. What you pay, 11.3 times trough EBITDA, looks expensive against Olin's own history, where it usually fetched 6 to 9 times, and cheap only if mid-cycle earnings return, when that same multiple would fall to roughly 5 times. The edge here is not spotting the turn, Q2 already showed it. It is judging whether the debt gets refinanced cheaply enough for equity holders to keep the upside, and the next few quarters of chlor-alkali pricing against the 2027 maturities settle that.

Management

Insiders have been sellers, not buyers. Over the past year five of them sold about $2.5M of stock and none bought a share, the largest a $2.07M sale by CFO Todd Slater in February at prices well above today's $17, with 10b5-1 status not disclosed in the filing. More telling is capital allocation. Olin repurchased $1.35B, $711M and $300M of its own stock across 2022, 2023 and 2024, at prices from the $40s to the $60s, then halted buybacks entirely in the first half of 2026 with the stock near $17. That is buying high and stopping at the low, and it is the clearest mark against a management now asking shareholders to trust its judgment on a large merger.

How it fails or surprises you

The debt wall closes before the cycle opens. Olin carries about $3.0B of long-term debt against roughly $460M of trough cash earnings, 6.6 times, and has not earned its interest from operations in a year. If chlorine pricing stalls into 2027 as maturities come due, refinancing at high rates hands the recovery's value to lenders and leaves equity a thin sliver on a big liability.

The Huntsman combination breaks or disappoints. The deal is agreed but not closed, and merging two levered cyclical chemical makers doubles balance-sheet risk if synergies lag or antitrust regulators carve into the chlorine and epoxy overlap. A collapse sends OLN back to a standalone story at a worse debt level, and a poor exchange ratio hands Olin holders too little of the combined upside.

Mid-cycle returns and the multiple re-rates (right tail). Chlorine and epoxy are deep troughs, not structural declines. If industrial demand firms and Chinese oversupply eases, Olin's mid-cycle earnings power is $1B-plus, the level it cleared in 2021 and 2022. Against today's $5.2B enterprise value that is under 5 times, with Winchester's steady profits thrown in nearly free. Q2's margin turn is the first tell.

Closing thoughts

The next few quarters' chlor-alkali pricing and the Huntsman deal terms will settle this, one way or the other. The cyclical turn is no longer the question, Q2 answered it. What is unresolved is whether the balance sheet lets equity holders keep the recovery, and whether OlinHuntsman closes on terms that help rather than dilute. The left tail, a refinancing at punitive rates into a stalled cycle, is fatter than 1.2 times book suggests, because 6.6 times leverage at the trough leaves little room, and if it breaks most of the equity value goes with it. The right tail, mid-cycle earnings against a $5.2B enterprise value, is worth a double or more.

The bet is still that Olin's chemical plants are at the bottom of a cycle, not broken, and that the company can carry more than $3B of debt long enough to merge with Huntsman and let prices climb back. What breaks it is the timing gap between the debt coming due and the cycle turning. Watch two numbers together: chlor-alkali pricing across the next two quarterly prints, and the closing progress and terms of the Huntsman deal. If margins keep climbing off Q2's 10% while the deal closes clean, the recovery is yours. If pricing stalls into the 2027 maturities, the lenders take it first.